Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623690 | 0.93 | HSD11B1 (0.70) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL3625182 | 0.87 | HSD11B1 (0.59) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL3623686 | 0.86 | HSD11B1 (1.00) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL12070487 | 0.80 | HSD11B1 (0.65) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL3625177 | 0.79 | HSD11B1 (0.63) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL3622012 | 0.78 | HSD11B1 (0.61) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL3620654 | 0.76 | HSD11B1 (0.60) | HSD11B1L3MBTL1EPHX2 | |
| SCHEMBL618834 | 0.75 | L3MBTL1 (0.59) | HSD11B1L3MBTL1EPHX2EPHX1 | |
| SCHEMBL25358145 | 0.74 | L3MBTL1 (0.68) | HSD11B1L3MBTL1EPHX2 | |
| SCHEMBL3620374 | 0.74 | HSD11B1 (0.61) | HSD11B1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | claimed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | HSD11B1 1/4885L3MBTL1 3653/4885EPHX2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.